Arkin Bio Ventures Limited Partnership 3
3 · Keros Therapeutics, Inc. · Filed Apr 7, 2020
Insider Transaction Report
Form 3
Holdings
Series B-1 Preferred Stock
→ Common Stock (343,270 underlying)Series A Preferred Stock
→ Common Stock (1,382,295 underlying)Series C Preferred Stock
→ Common Stock (167,537 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock is convertible at any time, at the holder's election, into Common Stock, on a one-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.